enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,497,488 shares, a growth of 32.4% from the December 15th total of 1,130,950 shares. Currently, 2.5% of the shares of the company are short sold. Based on an average daily trading volume, of 268,316 shares, the short-interest ratio is presently 5.6 days. Based on an average daily trading volume, of 268,316 shares, the short-interest ratio is presently 5.6 days. Currently, 2.5% of the shares of the company are short sold.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $9.31 on Friday. enGene has a one year low of $2.65 and a one year high of $11.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.30 and a quick ratio of 6.30. The company has a market cap of $623.63 million, a price-to-earnings ratio of -4.07 and a beta of -0.29. The firm has a 50 day simple moving average of $8.35 and a 200 day simple moving average of $6.52.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). Research analysts predict that enGene will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ENGN shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of enGene in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. Citizens Jmp lifted their price target on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 12th. Morgan Stanley increased their price target on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 12th. Finally, UBS Group lifted their price objective on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.38.

Institutional Trading of enGene

A number of hedge funds have recently made changes to their positions in ENGN. PFS Partners LLC grew its holdings in shares of enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after purchasing an additional 2,000 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in enGene in the 3rd quarter valued at approximately $76,000. Millennium Management LLC boosted its position in enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the period. Citadel Advisors LLC grew its holdings in enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock worth $399,000 after acquiring an additional 35,327 shares during the last quarter. Finally, Braidwell LP bought a new stake in enGene during the 3rd quarter worth approximately $15,479,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.